Journals / Türk Üroloji Dergisi/Turkish Journal of Urology / 2008 / Cilt: 34 - Sayı: 2

Impact of tissue matrix metalloproteinase and its inhibitors on prognosis of patients with renal cell carcinoma

Doku matriks metalloproteinaz ve inhibitörlerinin böbrek hücreli kanserin hastalık seyrine etkisi

Pages
149–154
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Considering the complex and paradoxic interactions of MMP and TIMP, there may be other factors affecting the prognosis by a different mechanism other than these two protein groups.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Introduction: Our aim was to determine the expression ratios of MMP-2, MMP-9 and TIMP-2 in patients with RCC and study the correlation between the expression of tissue matrix metalloproteineases with their inhibitors and the clinicopathologic variables of the patients and evaluate the impact of these clinicopathologic variables on the prognosis.
📊
Key Findings & Data:Materials and Methods: After exclusion of patients who received neoadjuvant therapies like embolization and/or immunotherapy, 72 patients (50 male, 22 female) with T1-3N0M0 clear cell pattern and minimum 2 years of follow-up who underwent radical nephrectomy for RCC between 1996 and 2004 were included in the study group.
💡
Conclusion & Impact:Conclusion: Considering the complex and paradoxic interactions of MMP and TIMP, there may be other factors affecting the prognosis by a different mechanism other than these two protein groups.
🔬Design:Research Article
📍Scope:2004 Verileri
⚙️Variables:Matriks metalloproteinaz 9 · Seyir · Geriyedönük çalışma

Abstract

Introduction: Our aim was to determine the expression ratios of MMP-2, MMP-9 and TIMP-2 in patients with RCC and study the correlation between the expression of tissue matrix metalloproteineases with their inhibitors and the clinicopathologic variables of the patients and evaluate the impact of these clinicopathologic variables on the prognosis. Materials and Methods: After exclusion of patients who received neoadjuvant therapies like embolization and/or immunotherapy, 72 patients (50 male, 22 female) with T1-3N0M0 clear cell pattern and minimum 2 years of follow-up who underwent radical nephrectomy for RCC between 1996 and 2004 were included in the study group. Cytoplasmic MMP-2, MMP-9 and TIMP-2 expressions were evaluated immunohistochemically with the percentage and intensity of the staining after pathologic evaluation. Results: The mean tumor size was 7.2 cm (2-22). Final pathology was T1N0M0, T2N0M0 and T3N0M0 in 51.4%, 38.9% and 9.7% of the patients, respectively. MMP-2, MMP-9 and TIMP-2 were positive in the 35%, 89% and 32% of the tumor cells, respectively. Clinical progression was detected in 11 (15.3%) patients in contrast to 61 (84.7%) of 72 patients who had no progression. We found a statistically significant positive correlation only between the clinic stage and TIMP-2 immunohistochemical staining score. Conclusion: Considering the complex and paradoxic interactions of MMP and TIMP, there may be other factors affecting the prognosis by a different mechanism other than these two protein groups.

Özet

Böbrek hücreli kanser (BHK) olan hastalarda MMP-2, MMP-9 ve TİMP-2 ekspresyon oranlarının belirlenmesi, doku matriks metalloproteinaz ve inhibitörlerinin ekspresyonunun hastaların klinikopatolojik değişkenleriyle korelasyonunun araştırılması ve bu klinikopatolojik değişkenlerin hastalığın seyrine olan etkisinin değerlendirilmesi amaçlanmıştır. Kliniğimizde, 1996 ve 2004 yılları arasında BHK için radikal nefrektomi uygulanan gruptan embolizasyon ve/veya immunoterapi gibi neoadjuvan tedavi almış olanlar çıkarıldıktan sonra minimum 2 yıllık takip süresi olan T1- 3N0M0 şeffaf hücre paternli toplam 72 hasta (50 erkek, 22 kadın) çalışmaya alındı. Patolojik değerlendirmeden sonra immünhistokimyasal olarak sitoplazmik MMP-2, MMP-9 ve TIMP-2 ekspresyonları boyanma yaygınlığı ve boyanma şiddetine göre değerlendirildi. Ortalama tümör boyutu 7.2 (2-22) cm olan hastaların %51.4’inde T1N0M0, %38.9’unda T2N0M0, %9.7’sinde ise T3N0M0 tümör tespit edildi. MMP-2, MMP-9 ve TIMP-2 tümör hücrelerinin sırasıyla %35, %89 ve %32’sinde pozitifti. Toplam 72 hastadan 11 (%15,3)’inde progresyon görüldü ve 61 (%84,7) hastada ise progresyon tespit edilmedi. İmmünhistokimyasal boyanma skoru değerlendirildiğinde sadece klinik evre ile TIMP-2 IBS arasında pozitif yönde istatistiksel olarak anlamlı ilişki bulundu. MMP ve TİMP’in paradoks ve kompleks etkileşimlerinin tespit edilmesi BHK’da muhtemelen bu iki protein grubundan farklı bir mekanizmayla hastalığın seyrini etkileyen başka bir etkenin varlığını düşündürebilir.

🔖

Cite This Article

GÜROCAK, Ö. S., SÖZEN, S., ÜRE, İ., ERDEM, Ö., AKYOL, G., ALKİBAY, T. (2008). Impact of tissue matrix metalloproteinase and its inhibitors on prognosis of patients with renal cell carcinoma. Türk Üroloji Dergisi/Turkish Journal of Urology, Cilt: 34 - Sayı: 2, 149–154. https://ajindex.com/articles/328720

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (18)

  1. Jemal A, Tiwari RC, Murray T, et al: Cancer statis- tics. CA Cancer J Clin, 54: 8, 2004
  2. Lam JS, Shvarts O, Leppert JT, et al: Renal cell carci- noma 2005: New frontiers in staging, prognostication and targeted molecular therapy. J Urol, 173: 1853-62, 2005
  3. Laber DA: Risk factors, classification and staging of re- nal cell cancer. Med Oncol, 23: 443-54, 2006
  4. Shuch BM, Lam JS, Balldegrun AS, et al: Prognostic factors in renal cell carcinoma. Semin Oncol, 33: 563-75, 2006
  5. Pantuck AJ, Zisman A, Belldegrun AS: The changing natural history of renal cell carcinoma. J Urol, 166: 1611- 23, 2001
  6. Catania JM, Chen G, Parrish AR: Role of matrix me- talloproteinases in renal pathophysiologies. Am J Physiol Renal Physiol, 292: F905-11, 2007
  7. Cho DS, Joo HJ, Oh DK: Cyclooxygenase-2 and p53 expression as prognostic indicators in conventional renal cell carcinoma. Yonsei Med J, 46: 133-40, 2005
  8. Perabo F, Sharma S, Gierer R, et al: Circulating inter- cellular adhesion molecule-1 (ICAM-1), vascular cell ad- hesion molecule-1 (VCAM-1) and E-selectin in urologi- cal malignancies. Indian J Cancer, 38: 1-7, 2001
  9. Kugler A: Matrix metalloproteinases and their inhibitors. Anticancer Res, 19: 1589-1592, 1999
  10. Carmeliet P, Moons L, Lijnen R, et al: Urokinase-ge- nerated plasmin activates matrix metalloproteinases du- ring aneurysm formation. Nat Genet, 17: 439-444, 1997
  11. Cornelius LA, Nehring LC, Harding E, et al: Matrix metalloproteinases generate angiostatin: Effects on neo- vascularization. J Immunol, 161: 6845-6852, 1998
  12. Gomez DE, Alonso DF, Yoshiji H, et al: Tissue inhibit- tors of metalloproteinases: Structure, regulation and bio- logical functions. Eur J Cell Biol, 74: 111-122, 1997
  13. Baker AH, Ahonen M, Kahari VM: Potential applicati- ons of tissue inhibitors of metalloproteinase (TIMP) over- expression for cancer gene therapy. Adv Exp Med Biol, 465: 469-483, 2000
  14. Novara G, Martignoni G, Artibani W, et al: Grading systems in renal cell carcinoma. J Urol, 177: 430-6, 2007
  15. Ficarra V, Galfano A, Mancini M, et al: TNM staging system for renal-cell carcinoma: Current status and future perspectives. Lancet Oncol, 8: 554-8, 2007
  16. Fidler IJ: Critical factors in the biology of human cancer metastasis: Twenty-eight G.H.A. Clowes Memorial Award Lecture. Cancer Res, 50: 6130-6138, 1990
  17. Stetler-Stevenson WG: Type-IV collagenases in tumor invasion and metastasis. Cancer Metastasis Rev, 9: 289- 303, 1990
  18. Declerck YA,